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This systematic review examined the use of incontinence-specific QOL measures in clinical 
trials of female incontinence treatments, and systematically evaluated their quality using a 
standard checklist. 
Of 61 trials included in the review, 58 (95.1%) used an incontinence-specific QOL measure.  The 
most commonly used were IIQ (19 papers), I-QoL (12 papers) and UDI (9 papers).  Eleven 
papers (18.0%) used measures which were not referenced or were developed specifically for the 
study.  The eight QOL measures identified had good clinical face validity and measurement 
properties. 
We advise researchers to evaluate carefully the needs of their specific study, and select the QOL 
measure that is most appropriate in terms of validity, utility and relevance, and discourage the 
development of new measures.  Until better evidence is available on the validity and 
comparability of measures, we recommend that researchers consider using IIQ or I-QOL with or 




Systematic review, incontinence-specific quality of life measures, outcome measurement, 




The most recent International Continence Society (ICS) definition of urinary incontinence (UI) is 
‘the complaint of any involuntary leakage of urine’ 1, however this definition does not take into 
account the wide variability in patient response to symptoms.  The previous ICS definition 
recognised the importance of not only UI symptoms, but also their impact on the patients and 
those around them: UI was defined as ‘the involuntary loss of urine which is objectively 
demonstrable and a social or hygienic problem’ 2.  In the recommendations for the 
standardisation of outcome measures for research in adult women with symptoms of lower 
urinary tract dysfunction, the Standardisation Committee of ICS accepted that UI has an impact 
on women's quality of life (QOL), suggesting that reliable and sensitive QOL questionnaires 
should be used in evaluating therapies for UI 3.  The guidelines did not recommend the use of 
specific QOL measures, nor did they give specific guidance on the best way to select measures.  
Four helpful review articles published recently, described a range of QOL measures for use in 
evaluating UI treatments, but did not quantify how widely individual measures are used 4-7. 
 
Treatments for UI for women are designed to improve symptoms and incontinence-related QOL, 
in circumstances when improvements might be considered a benefit, even if a cure is not 
possible.  In clinical trials designed to evaluate treatments, it is therefore important to measure 
change, not only in symptoms, but also to measure the impact of treatments on QOL.  Therefore 
in clinical trials of such treatments, the inclusion of a measure of QOL is particularly important.   
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We set out to examine the use of incontinence-specific QOL measures in clinical trials, by 
undertaking a systematic review of evaluations of incontinence treatments for women, where 
QOL measures had been used to assess outcome, and to review the quality of the QOL measures 





A two stage methodology was used to review the literature: first, a review of trials was 
undertaken to determine what outcome measures were being used.  Secondly, the quality of the 
outcomes was evaluated using a pre-defined checklist. 
 
Stage 1: Review of Measures used in Clinical Trials 
A systematic search of English language papers were carried out in PubMed (1966 to March 
2004).   The search used the words ‘urinary incontinence’ and ‘quality of life’ or ‘patient 
satisfaction’ or ‘patient perception’ or ‘health status’, and was limited to ‘English’, ‘human’, 
‘female’ and ‘clinical trial’.  Abstracts of all the papers were reviewed by one reviewer (SR).  
Review articles and editorials were excluded, as were papers that did not solely investigate 
women, did not use QOL as an outcome, or did not investigate a treatment for incontinence.  For 




All potentially relevant papers, including those describing behavioural, drug, surgical and 
management trials, were obtained and reviewed.  Data from the relevant papers were extracted 
and entered into an Excel database by SR, and details were checked by AK: disagreements were 
resolved by consensus, or by arbitration by DS.  For the purposes of analysis, where the details 
of the QOL measure used were not given in the paper, but a single reference was cited, then the 
details from the reference were used for analysis if these were sufficiently clear.  QOL measure 
details were described as 'unclear' if conflicting details were provided in references. 
 
Stage 2: Review of the Quality of Measures 
The review of the quality of measures used a checklist that was originally developed to evaluate 
QOL measures in the study of menorrhagia 8.  In addition to examining the more usual 
measurement properties (7 items), the evaluation also involves an examination of clinical 
validity (10 items).  For each of the measures identified, information was determined for each of 
the criteria in the checklist and entered into a Word table by SR for ease of comparison.  All data 




Stage 1: Review of Measures used in Clinical Trials 
The search identified 154 potentially relevant papers, published from 1991 to March 2004.  
Reasons for excluding papers were that: 27 papers did not solely investigate women (i.e. they 
included both male and female patients or children); 16 papers did not directly investigate a UI 
treatment (for example, papers that examined UI as an outcome of hysterectomy, spinal cord 
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injuries, multiple sclerosis, depression, pregnancy or cancer); 40 papers did not include QOL as 
an outcome measure; ten papers did not discuss a trial of a treatment for UI (including five 
descriptive studies, two studies investigating prevention of UI, two that validated a QOL 
measure, and one that described a trial design).  Thus the literature search yielded 61 papers that 
met the pre-defined criteria for inclusion, and reported QOL as an outcome. 
 
The 61 papers, published between 1991 and March 2004, 34 (55.7%) from North America and 
13 (21.3%) from Europe, described a wide range of studies, investigating a variety of 
interventions and employing a number of different research methods (Table 1).  Forty-six papers 
(75.4%) reported using an incontinence-specific QOL measures alone, 3 (4.9%) reported a 
generic health outcome only, and 12 (19.7%) reported using both types of measure.  Ten (16.4%) 
of the papers used an incontinence-specific QOL measure for which there was neither a 
reference, nor information about the development or testing of the measure 7;9-17, and one paper 
used a single question extracted from a validated measure 18.  Forty-seven (77.0%) papers used 
one of eight previously published incontinence-specific QOL measure (Table 2), of which the 
most commonly used were IIQ (reported in 19 papers), I-QoL (12 papers) and UDI (9 papers).  
The most frequently used combinations of incontinence-specific QOL measures were IIQ with 
UDI (8 papers.19-26), and IIQ-7 with UDI-6 (5 papers 25-29). 
 
Stage 2: Review of the Quality of Measures 
Each of the eight incontinence-specific QOL measures is described briefly in Table 3.  Each of 
the measures was reviewed using the evaluation checklist 8: clinical face validity is reported in 
Table 4, and measurement properties in Table 5.   
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 Clinical face validity appeared excellent for all measures (Table 4), except that none of the 
measures permitted supporting patient comments, or included patient ranking of important items.  
Six of the measures were designed to measure a variety of domains (IIQ, UDI, BFLUTS, I-QOL, 
KHQ and CONTILIFE), while the short forms of IIQ and UDI (IIQ-7 and UDI-6), YIPS and 
IQoLI each measure a single domain.  Composite scores were available for all but two measures 
(BFLUTS and KHQ).  A separate global QOL rating was available only for KHQ, differentiating 
this from “how much your bladder problem affects your life”.  All but one measure were 
developed from interviews with patients, and the items could therefore be regarded as relevant to 
patients.  Relevance of the measures for clinical assessment was judged to be acceptable for all 
measures using the definition of inclusion of two or more of: functional items, wellbeing, global 
evaluation of health or QOL 8.  
 
Measurement properties were reported for all the measures, although the type and quantity of 
evaluations varied considerably (Table 5).  Reliability, criterion or construct validity and 
responsiveness were reported for all the measures, and appeared acceptable.  Interpretability was 
difficult to examine, because the ranges of possible scores were different, and direction of scores 
varied: for IIQ, UDI, KHQ, BFLUTS and CONTILIFE, high scores represented most 
impairment or worst QOL; for I-QOL, YIPS and IQoLI high scores represented least impairment 
or best QOL.  One author presented suggestions for IIQ cut-off points for good, moderate or poor 
QOL 30, and a difference of at least 5 points was found to be the minimal important difference 
for KHQ 31.  Acceptability to patients was difficult to determine, because few validation studies 
reported the number of women contacted to achieve the number of completed questionnaires.  
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Feasibility was generally acceptable, although only I-QOL and KHQ were available in a broad 
range of languages.  A manual was available for only I-QOL. 
 
UDI, IIQ, I-QOL and KHQ were subject to independent testing in addition to that carried out by 
the developers of the measures (UDI 30;32-38, IIQ 33;36-39, I-QOL 40, KHQ 41;42).  In general, 





From the results of our study, we are able to report that IIQ is the most frequently used measure 
of incontinence-specific QOL, possibly because it was the first such measure published (in 
1994).43  I-QOL is also frequently used.  UDI is often used to complement these QOL measures 
by evaluating the distress caused by incontinence symptoms.  The short forms of IIQ (IIQ-7) and 
UDI (UDI-6) 44 are becoming more common, in order to reduce the burden of questionnaires on 
patients.   
 
The clinical face validity and measurement properties of these measures are excellent.  IIQ and 
UDI have been particularly well scrutinized by researchers not involved in the original 
development of the measures.  Although the reports by independent researchers are generally 
positive about IIQ and UDI, some have been critical.  The criticisms are as a result of finding 
poor correlation between pad test weights and IIQ and UDI scores 32;38.  We have previously 
commented that this could be rather as a result of problems with the pad test, than problems with 
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Despite the availability of QOL questionnaires, new questionnaires continue to appear, for 
example CONTILIFE 46 and ICIQ-UI Short Form 47.  The reasons for developing additional 
questionnaires are not clear, but could be related to the limited range of languages available in 
previously developed questionnaires.  CONTILIFE is available in six European languages, and 
ICIQ-UI Short Form in 30 languages, although validation data have yet to be published for all 
the ICIQ translations.  ICIQ-UI Short Form is too recent a development to appear in our 
systematic review. 
 
Although the majority of papers used referenced QOL measures, almost a fifth of the papers used 
outcomes for which there was neither a reference, nor information about the development or 
testing of the measure.  Given the wide availability of QOL measures in a number of languages, 
this practice is surprising and should be discouraged. 
 
Our study was limited to a review of a single database (PubMed).  The search was designed to be 
systematic rather than comprehensive, and therefore has not identified all evaluations using QOL 
measures, nor has it identified all UI measures known to us.  For example, Urge-UDI and Urge-
IIQ 48, and the Symptom Severity Index and Symptom Impact Index 49 were not found, however 
the most commonly used measures were identified.  Our search was limited to English language 
reports, and this may be regarded as a limitation, because we inevitably identified English 
questionnaires, and are unable to comment comprehensively on questionnaires in other 
languages.  Our recommendation includes both IIQ, available in a limited range of languages, 
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and I-QOL which is available in a number of languages.  Availability of a measure in a particular 
language may determine which measure is most appropriate in a particular setting.   
 
The results of our study lead us to advise researchers to evaluate carefully the needs of their 
specific study, and select the measure that is most appropriate in terms of validity, utility and 
relevance.  We can recommend the use of the checklist developed by Clarke et al for this 
purpose, because it provides a clear structure for evaluating and comparing different QOL 
measures 8. 
 
The use of standardised outcome measurement for incontinence-specific QOL is to be strongly 
encouraged, in order that the results of trials may be combined and compared.  We recently 
pointed out the difficulty in gathering and synthesising meaningful data on incidence and 
prevalence of UI, because of the variety in definitions of UI 50: the situation is similar in relation 
to the measurement of outcome in trials.  Without standardisation of measures of incontinence-
specific QOL, we will continue to be in the situation where meta-analysis of data is impossible 
because of the plethora of instruments, the use of un-validated measures, and the inability to 
combine data from different measures.   
 
This view was reiterated recently by the ICS, and the most recent recommendations from the 
Third International Consultation on Incontinence will be published in June 2005 
(www.continet.org).  We believe that our review adds to that work by being more specific about 
measures for use in urogynaecology, and by highlighting the measures that are actually in current 
use, as opposed to the more usual reviews of the complete range of measures available  4-7. 
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 Although a number of measures were used frequently, better evidence is needed before 
concluding which single questionnaire should be considered the gold standard.  Until that 
evidence becomes available, we recommend that researchers consider using IIQ or I-QOL with 
or without UDI as their first choice of QOL measures in trials of incontinence treatments.  Our 
recommendation is based on the assessment of validity, reliability, responsiveness, utility, and 
frequency of use of these measures.  Consistent use of IIQ or I-QOL with or without UDI would 




Table 1 Description of papers included in the review of QOL measures 
 




Treatment under investigation *  
Pelvic floor muscle training 
(exercises, vaginal cones or 
electrical/magnetic stimulation) 
21 (34.4%) 10;11;13;19;51-60 
Surgical interventions, including 
bulking agents 
13 (21.3%) 12;15;17;18;21;27;28;61;61-66 
Pharmacological agents 12 (19.7%) 14;24;29;67-75 
Educational/ behavioural intervention 11 (18.0%) 9;23;76-84 
Urethral or vaginal devices 8 (13.1%) 16;20;22;85-89 
Specialist nurses 2 (  3.2%) 25;26 
Acupuncture 1 (  1.6%) 90 
Research design $   
Randomised and quasi-randomised 
trials 
19 (31.1%) 9-11;15;19;21;23-26;52;58;60;64-69;71-77;79-84;88 
Prospective studies (eg case series, 
multi centre series) 
43 (70.5%) 11-14;16-18;20;22;27-29;51;53-57;59;61-63;70;78;85-87;89;90 
Notes:  
* Seven papers examined multiple interventions 9;23;80-84 
$ One paper reported a prospective study and an RCT 11 
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Table 2 Incontinence-specific measures reported (among the papers which reported 









IIQ *   
IIQ (full version) 43 19 (32.8%) 19-26;54;61;68;76;77;79;80;82-84;89  
IIQ-7 44 6 (10.3%) 25-29;81 
UDI   
UDI (full version) 43 9 (15.5%) 19-26;87 
UDI-6 44 5 (  8.6%) 25-29 
I-QoL 91 12 (20.7%) 51;55-57;69-71;73;75;81;85;86 
BFLUTS 92 5 (  8.6%) 53;59;60;65;67 
KHQ 93 4 (  6.9%) 52;62;72;74 
CONTILIFE 46 2 (  3.4%) 63;66 
YIPS 79 1 (  1.7%) 79 
IQoLI 94 1 (  1.7%) 90 
Other (unreferenced) measure 11 (19.0%) 9-18 
Note: 
* One paper presented both the long and short forms of UDI and IIQ 25. 
IIQ:   Incontinence Impact Questionnaire 
UDI:   Urogenital Distress Inventory 
I-QOL: Incontinence QOL instrument 
BFLUTS: Bristol Female Lower Urinary Tract Symptoms questionnaire 
KHQ:  King’s Health Questionnaire 
YIPS:  York Incontinence Perception Scale 
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